MitoPharms Begins Production of its Anti-Aging Products

MitoPharm today announce they have started production of its anti-aging and stamina improvement product line.

Seattle, WA (PRWEB) October 15, 2007 -- MitoPharm Corporation, Inc. (Pinksheets: MTPM), today announce they have started production of its anti-aging and stamina improvement product line.

Through contractual arrangement, a manufacturer in China with state-of-the-art production facility is taking part in the first commercial scale production of its products, utilizing a new commercial - scale process for the first-phase extraction of "(-) Schisandrin B" and "Schisandrin B", under directives of the Chief Technology Officer of MitoPharm, Dr. Robert Ko.

The decision to include others in the manufacturing process is an indication of MitoPharms's continuing commitment to meeting its production schedule for the anti-aging and stamina products.

For further information, shareholders and non-shareholders are encouraged to contact the Company's Investor Relations.

MitoPharm Corporation Investor Relations

800-858-7502

ir(at)mitopharm.com

About MitoPharm

MitoPharm, Inc. www.mitopharm.com is a biotechnology company in the research & development, marketing, and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly formulated compound (the "Compound") that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology ("HKUST").

Forward-Looking Statements

This news release includes forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the Company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the Company at this time, actual results may differ materially from those described. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) our ability to manage the HPW acquisition and the expansion of operations; (2) our ability to obtain contracts with suppliers of raw materials and distributors of our products; (3) the risks inherent in the mutual performance of such supplier and distributor contracts (including our production performance); (4) our ability to protect and defend our proprietary technology; (5) our ability to secure and retain management capable of managing growth; (6) our ability to raise necessary financing to execute the Company's business plans; and (7) the Company's ability to comply with all applicable federal, state and local government and international rules and regulations

###

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.